In addition, patients in low RIS group benefit more from anti-PD-1 immunotherapy than high RIS group (Fig. 5b), implying that RIS model might be a practical strategy to predict immunotherapeutic response in advanced HCC patients. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.